Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/β-catenin signaling

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages

  Zhang, Xiaoping ^a   Li, Maoquan ^a   Zuo, Keqiang ^a   Li, Dan ^a   Ye, Meng ^a   Ding, Lanbao ^a   Cai, Haidong ^a   Fu, Da ^a   Fan, Youben ^b   Lv, Zhongwei ^a  

^a TONGJI UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; LENTIVIRUS VECTOR; MICRORNA 155; WNT PROTEIN;

3' UNTRANSLATED REGION; APC GENE; ARTICLE; CELL GROWTH; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CYCLIN D1 GENE; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEF 1 GENE; ONCOGENE; ONCOGENE C MYC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TCF 1 GENE; THYROID CARCINOMA; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; WNT SIGNALING PATHWAY;

3' UNTRANSLATED REGIONS; ANIMALS; BETA CATENIN; CARCINOMA; CELL PROLIFERATION; GENES, APC; HUMANS; MALE; MICE; MICRORNAS; THYROID NEOPLASMS; UP-REGULATION; WNT SIGNALING PATHWAY;

EID: 84881485595     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3602     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RASBRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest. 2005;115:1068-1081.
3. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63:1454-1457.
4. Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G. Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci. 2002;963:116-121.
5. Fagin JA. Branded from the start: distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol. 2002; 16:903-911.
6. Castellone MD, De Falco V, Rao DM, et al. The β-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res. 2009;69:1867-1876.
7. Hoppler S, Kavanagh CL. Wnt signalling: variety at the core. J Cell Sci. 2007;120:385-393.
8. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006; 281:22429-22433.
9. Clevers H. Wnt/β-catenin signaling in development and disease. Cell. 2006;127:469-480.
10. MoonRT, Kohn AD, DeFerrari GV, Kaykas A. WNT and β-catenin signalling: diseases and therapies. Nat Rev Genet. 2004;5:691-701.
11. MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9-26.
12. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
13. Ambros V. The functions of animal microRNAs. Nature. 2004;431: 350-355.
14. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133: 647-658.
15. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449:682-688.
16. Ambs S, Prueitt RL, Yi M, et al. Genomic profiling ofmicroRNAand messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68:6162-6170.
17. Brest P, Lassalle S, Hofman V, et al. MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer. 2011;18:711-719.
18. Xiong Y, Zhang L, Holloway AK, Wu X, Su L, Kebebew E. MiR-886-3p regulates cell proliferation and migration, and is dysregulated in familial non-medullary thyroid cancer. PLoS One. 2011;6: e24717.
19. Zhang J, Liu Y, Liu Z, et al. Differential expression profiling and functional analysis of microRNAs through stage I-III papillary thyroid carcinoma. Int J Med Sci. 2013;10:585-592.
20. Jiang S, Zhang HW, Lu MH, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010;70:3119-3127.
21. Zhang P, Bill K, Liu J, et al. MiR-155 is a liposarcoma oncogene that targets casein kinase-1 and enhances β-catenin signaling. Cancer Res. 2012;72:1751-1762.
22. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab. 2008;93: 1600-1608.
23. Yip L, Kelly L, Shuai Y, et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011;18:2035-2041.
24. DeLellis R, Lloyd R, Heitz P, Eng C, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004.
25. Cheng SP, Yin PH, Chang YC, Lee CH, Huang SY, Chi CW. Differential roles of leptin in regulating cell migration in thyroid cancer cells. Oncol Rep. 2010;23:1721-1727.
26. Gao Y, Wang C, Shan Z, et al. miRNA expression in a human papillary thyroid carcinoma cell line varies with invasiveness. Endocr J. 2010;57:81-86.
27. Sztankay A, Trieb K, Lucciarini P, Steiner E, Grubeck-Loebenstein B. Interferon and iodide increase the inducibility of the 72 kD heat shock protein in cultured human thyroid epithelial cells. J Autoimmun. 1994;7:219-230.
28. Su Y, Fu C, Ishikawa S, et al. APC is essential for targeting phosphorylated β-catenin to the SCF-TrCP ubiquitin ligase. Mol Cell. 2008;32:652-661.
29. Eis PS, TamW, Sun L, et al. Accumulation of miR-155 and BICRNA in human B cell lymphomas. Proc Natl Acad Sci U S A. 2005;102: 3627-3632.
30. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257-2261.
31. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425-433.
32. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A. 2006;103:7024-7029.
33. Gironella M, Seux M, Xie MJ, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007;104:16170-16175.
34. Kong W, He L, Coppola M, et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 2010;285:17869-17879.
35. Kong KL, Kwong DL, Chan TH, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61:33-42.
36. Valeri N, Gasparini P, Fabbri M, et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A. 2010;107:6982-6987.
37. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843-850.
38. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science. 2000;287:1606-1609.
39. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of β-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999;59: 1811-1815.
40. Motti ML, Califano D, Baldassarre G, et al. Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis. 2005;26:1021-1034.